ArticleJournal for immunotherapy of cancer2026

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Cecilia Pesini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.